Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: Effectiveness and cost-effectiveness

Cancer

Volumn 95, Issue 9, 2002, Pages 1848-1856

  Reyes, Carolina M ^a   Allen, Brian A ^b   Terdiman, Jonathan P ^b   Wilson, Leslie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Colorectal carcinoma; Cost; Cost effectiveness; Genetic testing; Guidelines; HNPCC; MLH1; MSH2; Outcomes

Indexed keywords

PROTEIN MLH1; PROTEIN MSH2;

ARTICLE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MICROSATELLITE INSTABILITY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL;

BASE PAIR MISMATCH; CARRIER PROTEINS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; DNA REPAIR; DNA, NEOPLASM; DNA-BINDING PROTEINS; GENETIC SCREENING; GERM-LINE MUTATION; HETEROZYGOTE DETECTION; HUMANS; MICROSATELLITE REPEATS; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS;

EID: 0036840371     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10910     Document Type: Article

References (26)

1. Vasen HF, Wijnen IT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110:1020-1027.
2. Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med. 1998;129:787-796.
3. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829-834.
4. Vasen HF, Van Ballegooijen M, Buskens E, et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer. 1998;82:1632-1637.
5. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001;135:577-588.
6. Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev. 2000;24:137-142.
7. Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology. 1997;113:1146-1158.
8. Boland CR, Sato J, Saito K, et al. Genetic instability and chromosomal aberrations in colorectal cancer: A review of the current models. Cancer Detect Prev. 1998;22:377-382.
9. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: Meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89:1758-1762.
10. Salovaara R, Loukala A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193-2200.
11. Terdiman JP, Gum JR, Conrad PG, et al. Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology 2001;120:21-30.
12. Syngal S, Fox EA, Li C, et al. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: Implications for clinical predisposition testing. JAMA. 1999;282:247-253.
13. Wijnen JT, Vasen HF, Khan M, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med. 1998;339:511-518.
14. Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;121:198-213.
15. Peel DJ, Ziogas A, Fox EA, et al. Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases. J Natl Cancer Inst. 2000;92:1517-1522.
16. Riegler G, Savastano A, Selvaggi F, et al. Prevalence of HNPCC in a series of consecutive patients on the first endoscopic diagnosis of colorectal cancer: A multicenter study. The Italian Collaborative Group. Endoscopy. 1999;31:337-341.
17. Evans DG, Walsh S, Jeacock J, et al. Incidence of hereditary non-polyposis colorectal cancer in a population-based study of 1137 consecutive cases of colorectal cancer. Br J Surg. 1997;84:1281-1285.
18. Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet. 2000;37:641-645.
19. Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med. 1997;336:823-827.
20. Lerman C. Genetic testing in families with hereditary non-polyposis colon cancer. JAMA. 1999;281:1618-1622.
21. Petersen GM, Brensinger JD, Johnson KM, Fiardiello FM. Genetic testing and counseling for hereditary forms of colorectal cancer. Cancer Suppl. 1999;86:2540-2550.
22. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999;36:801-813.
23. Muller H, Dobbie Z, Heinimann K. Identification and genetic counseling of people with HNPCC (hereditary nonpolyposis colorectal cancer): Old and new research goals. Schweiz Med Wochenschr. 1999;129:1978-1985.
24. Davis JB. Medical Fees in the United States. Los Angeles: Practice Management Info. Corp., 2001.
25. Burt RW. Rare syndromes and genetic testing for colorectal cancer. Semin Gastrointest Dis. 2001;11:147-151.
26. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001;10:917-923.